While it is not frequently reported in normal prostate tissue, TMPRSS2:ERG fusions facilitate tumour progression by promoting angiogenesis, inflammation, and epithelial–mesenchymal transition ultimately leading to metastasis, advanced tumour stages, and increased mortality (32–34). The gene discussed is ERG; the disease is neoplasm.